The following tables presents the Company’s revenues by Group and End Customer Geography (in millions):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Revenue by Group:
Bruker BioSpin	$	175.7		$	186.5		$	493.3		$	494.4
Bruker CALID		207.5			194.2			601.0			579.9
Bruker Nano		199.1			174.9			559.8			504.6
BEST		59.3			57.0			178.2			166.0
Eliminations		(2.7	)		(3.7	)		(10.0	)		(10.5	)
Total revenue	$	638.9		$	608.9		$	1,822.3		$	1,734.4

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Revenue by End Customer Geography:
United States	$	191.8		$	163.2		$	518.3		$	442.0
Germany		51.9			55.5			177.7			186.4
Rest of Europe		151.7			155.4			425.4			459.9
China		111.6			105.4			291.0			252.6
Rest of Asia Pacific		85.1			86.2			271.1			273.2
Other		46.8			43.2			138.8			120.3
Total revenue	$	638.9		$	608.9		$	1,822.3		$	1,734.4

Revenue for the Company recognized at a point in time versus over time is as follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Revenue recognized at a point in time	$	557.0	$	530.8	$	1,580.2	$	1,503.0
Revenue recognized over time		81.9		78.1		242.1		231.4
Total revenue	$	638.9	$	608.9	$	1,822.3	$	1,734.4

Remaining performance obligations represent the aggregate transaction price allocated to a promise to transfer a good or service that is fully or partially unsatisfied at the end of the period. As of September 30, 2022, remaining performance obligations were approximately $2,013.3 million. The Company expects to recognize revenue on approximately 78% of the remaining performance obligations over the next twelve months and the remaining performance obligations primarily within one to three years.

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, note receivables and unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Company’s unaudited condensed consolidated balance sheets.

Contract assets—Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Billing often occurs subsequent to revenue recognition, resulting in contract assets. Contract assets are generally classified as other current assets in the unaudited condensed consolidated balance sheets. The balance of contract assets as of September 30, 2022 and December 31, 2021 was $60.1 million and $46.1 million, respectively.

Contract liabilities—The Company often receives cash payments from customers in advance of the Company’s performance, resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the unaudited condensed consolidated balance sheets based on the timing of when revenue recognition is expected. As of September 30, 2022 and December 31, 2021, the contract liabilities were $408.4 million and $430.8 million, respectively. The decrease in the contract liability balance during the nine months ended September 30, 2022 is primarily the result of satisfying performance obligations and foreign currency translation which were offset in part by new cash payments received. Approximately $261.4 million of the contract liability balance on December 31, 2021 was recognized as revenue during the nine months ended September 30, 2022.